Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients

Molecular Oncology

Volumn 9, Issue 4, 2015, Pages 850-860

  Mohamed Suhaimi, Nur Afidah ^a   Foong, Yu Miin ^a   Lee, Daniel Yoke San ^a   Phyo, Wai Min ^a   Cima, Igor ^a   Lee, Esther Xing Wei ^a   Goh, Wei Lin ^b   Lim, Wei Yen ^c   Chia, Kee Seng ^c   Kong, Say Li ^d   Gong, Min ^d   Lim, Bing ^d   Hillmer, Axel M ^d   Koh, Poh Koon ^a,b   Ying, Jackie Y ^a   Tan, Min Han ^a,e  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^b Fortis Healthcare Singapore   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

^e DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Circulating tumor cells; Colorectal cancer; Non invasive; Targeted phenotyping

Indexed keywords

B RAF KINASE; GENOMIC DNA; K RAS PROTEIN; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CODON; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DNA EXTRACTION; DNA TEMPLATE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PYROSEQUENCING; QUALITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; COLORECTAL TUMOR; DNA DENATURATION; GENETICS; GENOTYPING TECHNIQUE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR EMBOLISM;

ADULT; AGED; ALLELES; BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASTIC CELLS, CIRCULATING; NUCLEIC ACID DENATURATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 84926420107     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.12.011     Document Type: Article

References (34)

1. Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., Tibbe A.G., Uhr J.W., Terstappen L.W. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004, 10:6897-6904.
2. Asghar U., Hawkes E., Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin. Colorectal Cancer 2010, 9:274-281.
3. Bihl M.P., Hoeller S., Andreozzi M.C., Foerster A., Rufle A., Tornillo L., Terracciano L. KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13. Diagn. Mol. Pathol. 2012, 21:14-23.
4. Cima I., Chay W.Y., Iliescu F.S., Phyo W.M., Lim K.H., Iliescu C., Tan M.H. Label-free isolation of circulating tumor cells in microfluidic devices: current research and perspectives. Biomicrofluidics 2013, 7:11810.
5. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., Di Fiore F., Gangloff A.O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T.P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
6. Feng Y.-Z., Shiozawa T., Miyamoto T., Kashima H., Kurai M., Suzuki A., Konishi I. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin. Cancer Res. 2005, 11:6133-6138.
7. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
8. Franklin W.A., Haney J., Sugita M., Bemis L., Jimeno A., Messersmith W.A. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J.Mol. Diagn.: JMD 2010, 12:43-50.
9. Gasch C., Bauernhofer T., Pichler M., Langer-Freitag S., Reeh M., Seifert A.M., Mauermann O., Izbicki J.R., Pantel K., Riethdorf S. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal Cancer. Clin. Chem. 2013, 59:252-260.
10. Harb W., Fan A., Tran T., Danila D.C., Keys D., Schwartz M., Ionescu-Zanetti C. Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl. Oncol. 2013, 6:528-538.
11. Hüsemann Y., Geigl J.B., Schubert F., Musiani P., Meyer M., Burghart E., Forni G., Eils R., Fehm T., Riethmüller G., Klein C.A. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
12. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.-J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal Cancer. New Engl. J. Med. 2008, 359:1757-1765.
13. Klein C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9:302-312.
14. Kosmidou V., Oikonomou E., Vlassi M., Avlonitis S., Katseli A., Tsipras I., Mourtzoukou D., Kontogeorgos G., Zografos G., Pintzas A. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA Pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. Hum. Mutat. 2014, 35:329-340.
15. Lang A.H., Drexel H., Geller-Rhomberg S., Stark N., Winder T., Geiger K., Muendlein A. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J.Mol. Diagn.: JMD 2011, 13:23-28.
16. Langenbeck On the development of cancer in the veins, and the transmission of cancer from man to the lower animals. Edinb. Med. Surg. J. 1841, 55:251-253.
17. Laurent-Puig P., Cayre A., Manceau G., Buc E., Bachet J.-B., Lecomte T., Rougier P., Lievre A., Landi B., Boige V., Ducreux M., Ychou M., Bibeau F., Bouché O., Reid J., Stone S., Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J.Clin. Oncol. 2009, 27:5924-5930.
18. Lee J., Lee I., Han B., Park J.O., Jang J., Park C., Kang W.K. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J.Natl. Cancer Inst. 2011, 103:674-688.
19. Lim L.S., Hu M., Huang M.C., Cheong W.C., Gan A.T.L., Looi X.L., Leong S.M., Koay E.S.-C., Li M.-H. Microsieve lab-chip device for rapid enumeration and fluorescence in situ hybridization of circulating tumor cells. Lab Chip 2012, 12:4388-4396.
20. Mego M., Mani S.A., Cristofanilli M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat. Rev. Clin. Oncol. 2010, 7:693-701.
21. Modest D.P., Stintzing S., Laubender R.P., Neumann J., Jung A., Giessen C., Haas M., Aubele P., Schulz C., Boeck S., Stemmler H.J., Kirchner T., Heinemann V. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs 2011, 22:913-918.
22. Mostert B., Jiang Y., Sieuwerts A.M., Wang H., Bolt-de Vries J., Biermann K., Kraan J., Lalmahomed Z., van Galen A., de Weerd V., van der Spoel P., Ramírez-Moreno R., Verhoef C., Ijzermans J.N.M., Wang Y., Gratama J.-W., Foekens J.A., Sleijfer S., Martens J.W.M. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int. J. Cancer 2013, 133:130-141.
23. Paget J. Lectures on Surgical Pathology 1853, 536-581. Longrnan, Brown,Green, & Longman, London. second ed.
24. Peeters M., Oliner K.S., Parker A., Siena S., Van Cutsem E., Huang J., Humblet Y., Van Laethem J.-L., André T., Wiezorek J., Reese D., Patterson S.D. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal Cancer. Clin. Cancer Res. 2013, 19:1902-1912.
25. Powell A.A., Talasaz A.H., Zhang H., Coram M.A., Reddy A., Deng G., Telli M.L., Advani R.H., Carlson R.W., Mollick J.A., Sheth S., Kurian A.W., Ford J.M., Stockdale F.E., Quake S.R., Pease R.F., Mindrinos M.N., Bhanot G., Dairkee S.H., Davis R.W., Jeffrey S.S. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012, 7:e33788.
26. Price T.J., Hardingham J.E., Lee C.K., Weickhardt A., Townsend A.R., Wrin J.W., Chua A., Shivasami A., Cummins M.M., Murone C., Tebbutt N.C. Impact of KRAS and BRAF gene gutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J.Clin. Oncol. 2011, 29:2675-2682.
27. Raimondi C., Nicolazzo C., Gradilone A., Giannini G., De Falco E., Chimenti I., Varriale E., Hauch S., Plappert L., Cortesi E., Gazzaniga P. Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer. Cancer Biol. Ther. 2014, 15:0-1.
28. Richman S.D., Seymour M.T., Chambers P., Elliott F., Daly C.L., Meade A.M., Taylor G., Barrett J.H., Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J.Clin. Oncol. 2009, 27:5931-5937.
29. Sgambato A., Casaluce F., Maione P., Rossi A., Rossi E., Napolitano A., Palazzolo G., Bareschino M., Schettino C., Sacco P.C., Ciardiello F., Gridelli C. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation. Curr. Med. Chem. 2012, 19:3337-3352.
30. Simi L., Pratesi N., Vignoli M., Sestini R., Cianchi F., Valanzano R., Nobili S., Mini E., Pazzagli M., Orlando C. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am. J. Clin. Pathol. 2008, 130:247-253.
31. Spizzo G., Fong D., Wurm M., Ensinger C., Obrist P., Hofer C., Mazzoleni G., Gastl G., Went P. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J.Clin. Pathol. 2011, 64:415-420.
32. Tsiatis A.C., Norris-Kirby A., Rich R.G., Hafez M.J., Gocke C.D., Eshleman J.R., Murphy K.M. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J.Mol. Diagn.: JMD 2010, 12:425-432.
33. Yokota T., Ura T., Shibata N., Takahari D., Shitara K., Nomura M., Kondo C., Mizota A., Utsunomiya S., Muro K., Yatabe Y. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br. J. Cancer 2011, 104:856-862.
34. Zuo Z., Chen S.S., Chandra P.K., Galbincea J.M., Soape M., Doan S., Barkoh B.A., Koeppen H., Medeiros L.J., Luthra R. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod. Pathol. 2009, 22:1023-1031.